Checkpoint Therapeutics (CKPT)
(Delayed Data from NSDQ)
$2.43 USD
-0.03 (-1.22%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $2.45 +0.02 (0.82%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.43 USD
-0.03 (-1.22%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $2.45 +0.02 (0.82%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Zacks News
What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock
by Zacks Equity Research
Checkpoint Therapeutics (CKPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Checkpoint Therapeutics, Inc. (CKPT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Checkpoint Therapeutics, Inc. (CKPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Checkpoint Therapeutics, Inc. (CKPT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Checkpoint Therapeutics, Inc. (CKPT) delivered earnings and revenue surprises of -45.45% and -98.08%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Checkpoint Therapeutics, Inc. (CKPT) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Checkpoint Therapeutics, Inc. (CKPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Checkpoint Therapeutics, Inc. (CKPT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Checkpoint Therapeutics, Inc. (CKPT) delivered earnings and revenue surprises of 34.29% and -65.68%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Why Checkpoint Therapeutics (CKPT) Might Be a Diamond in the Rough
by Zacks Equity Research
Although overlooked by the investors, Checkpoint Therapeutics (CKPT) looks well positioned for a solid gain evident from its favorable Zacks rank and positive estimate revision.